Lumida
/BNTC
⌘K
Benitec Biopharma Inc

Benitec Biopharma Inc

BNTC
$12.19USD-0.25%-0.03 today

MARKET CAP

418.8M

P/E (TTM)

FWD P/E

DAY RANGE

$12 – $13

52W RANGE

$10
$17

AI Summary

Stalk
Buy NowMedium

The asset remains in a healthy Stage 2 uptrend, supported by a clear HH/HL sequence and active Lockout Rally dynamics. While a Bullish Exhaustion pattern signals momentum fatigue at recent highs, price is now pulling back into rising 9/21 EMAs at structural support, offering an attractive entry for continuation. The Lockout Rally override confirms short-term execution readiness despite overbought readings, and medium-term bullish bias persists within Stage 2, though near-term resistance at the 200 DMA and exhaustion risks warrant caution.

  • 80% upside potential as analysts set $24.80 target
  • Q2 EPS loss of $0.24 beats estimates of -$0.27
  • Earnings yield deeply negative, reflecting low return generation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2021FY 2022TREND
Sales, Adj.$102,000$59,000$73,000
YoY %-42.2%+23.7%
P / Sales79.2x309.4x129.9x
EV / Sales-3.7x-2.4x116.6x
Gross Profit, Adj.$102,000$59,000$73,000
YoY %-42.2%+23.7%
Margin %100.0%100.0%100.0%
EV / Gross Profit-3.7x-2.4x116.6x
EBITDA, Adj.$-8.1M$-13.4M$-17.7M
YoY %-65.2%-32.3%
Margin %-7932.4%-22652.5%-24228.8%
EV / EBITDA0.0x0.0x-0.5x
EBIT$-8.3M$-13.6M$-17.9M
YoY %-64.2%-31.3%
Margin %-8118.6%-23044.1%-24457.5%
EV / EBIT0.0x0.0x-0.5x
Net Income$-8.3M$-13.9M$-18.2M
YoY %-67.8%-31.2%
Net Margin-8111.8%-23528.8%-24942.5%
EPS (GAAP)-$137.70-$54.91-$37.91
YoY %+60.1%+31.0%